Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders Equity (Deficit) - USD ($) $ in Thousands	Common Stock	Preferred Stock Series B1 Preferred	Preferred Stock Series Z preferred stock	Preferred Stock Series B Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Other Comprehensive Income (Loss)	Total
Temporary equity, Beginning balance (in shares) at Dec. 31, 2020		23,684
Increase (Decrease) in Temporary Equity
Conversion of Series B1 preferred stock (in shares)		(23,684)
Beginning balance at Dec. 31, 2020	$ 2				$ 742,378	$ (833,552)		$ (91,172)
Beginning balance (in shares) at Dec. 31, 2020	2,252,390
Increase (Decrease) in Stockholders' Equity
Sale of common stock, net of issuance costs	$ 1				19,514			19,515
Sale of common stock, net of issuance costs (in shares)	348,079
Conversion of Series B1 preferred stock (in shares)	139,317
Issuance of common stock under employee stock purchase plan					59			59
Issuance of common stock under employee stock purchase plan (in shares)	2,889
Issuance of common stock under equity incentive plan (vesting of restricted stock units) (in shares)	13,927
Issuance of common stock upon exercise of common stock options and warrants					271			271
Issuance of common stock upon exercise of common stock options and warrants (in shares)	345,332
Issuance of common stock for services rendered					152			152
Issuance of common stock for services rendered (in shares)	5,013
Stock-based compensation expense					2,537			2,537
Net (loss) income						98,091		98,091
Ending balance at Dec. 31, 2021	$ 3				764,911	(735,461)		$ 29,453
Ending balance (in shares) at Dec. 31, 2021	3,106,947							3,106,947
Increase (Decrease) in Temporary Equity
Issuance of preferred stock upon Acquisition of Aceragen			$ 27,108
Issuance of preferred stock upon Acquisition of Aceragen (in shares)			77,663
Vesting of restricted stock awards (in shares)			237
Temporary equity, Ending balance at Dec. 31, 2022			$ 27,108
Temporary equity, Ending balance (in shares) at Dec. 31, 2022			77,900
Increase (Decrease) in Stockholders' Equity
Sale of common stock, net of issuance costs					(15)			$ (15)
Issuance of common stock under employee stock purchase plan					49			49
Issuance of common stock under employee stock purchase plan (in shares)	7,788
Common stock dividend issued in the form of Series B Preferred Stock				$ 1				1
Common stock dividend issued in the form of Series B Preferred Stock (in shares)				62,355
Issuance of common stock under equity incentive plan (vesting of restricted stock units) (in shares)	1,600
Vesting of restricted stock awards (in shares)	1,331
Issuance of common stock upon exercise of common stock warrants					15			15
Issuance of common stock upon exercise of common stock warrants (in shares)	90,185
Issuance of common stock for services rendered					88			88
Issuance of common stock for services rendered (in shares)	10,989
Stock-based compensation expense					2,188			2,188
Issuance of common stock upon Acquisition of Aceragen	$ 1				3,427			3,428
Issuance of common stock upon Acquisition of Aceragen (in shares)	434,845
Currency translation adjustment							$ (21)	(21)
Net (loss) income						(23,360)		(23,360)
Ending balance at Dec. 31, 2022	$ 4			$ 1	$ 770,663	$ (758,821)	$ (21)	$ 11,826
Ending balance at Dec. 31, 2022				62,355
Ending balance (in shares) at Dec. 31, 2022	3,653,685							3,653,685